Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Psychostimulant effect of levodopa: reversing sensitisation is possible.

Castrioto A, Kistner A, Klinger H, Lhommée E, Schmitt E, Fraix V, Chabardès S, Mertens P, Quesada JL, Broussolle E, Pollak P, Thobois SC, Krack P.

J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):18-22. doi: 10.1136/jnnp-2012-302444.

PMID:
22991345
2.

Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.

Lhommée E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabardès S, Seigneuret E, Benabid AL, Mertens P, Polo G, Carnicella S, Quesada JL, Bosson JL, Broussolle E, Pollak P, Krack P.

Brain. 2012 May;135(Pt 5):1463-77. doi: 10.1093/brain/aws078.

3.

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P.

Brain. 2010 Apr;133(Pt 4):1111-27. doi: 10.1093/brain/awq032.

4.

SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson's disease.

Nunta-Aree S, Sitthinamsuwan B, Boonyapisit K, Pisarnpong A.

J Med Assoc Thai. 2010 May;93(5):529-40.

PMID:
20524438
5.

Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.

Simonin C, Tir M, Devos D, Kreisler A, Dujardin K, Salleron J, Delval A, Blond S, Defebvre L, Destée A, Krystkowiak P.

J Neurol. 2009 Oct;256(10):1736-41. doi: 10.1007/s00415-009-5195-2.

PMID:
19536584
6.

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P.

N Engl J Med. 2003 Nov 13;349(20):1925-34.

7.

Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA, Lanotte M, Rizzone MG, Lopiano L.

Brain. 2011 Jul;134(Pt 7):2074-84. doi: 10.1093/brain/awr121.

8.

Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.

Funkiewiez A, Ardouin C, Krack P, Fraix V, Van Blercom N, Xie J, Moro E, Benabid AL, Pollak P.

Mov Disord. 2003 May;18(5):524-30.

PMID:
12722166
9.

Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease.

Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ.

Arch Gen Psychiatry. 2003 Mar;60(3):296-302.

PMID:
12622663
10.

Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.

Moro E, Esselink RJ, Benabid AL, Pollak P.

Brain. 2002 Nov;125(Pt 11):2408-17.

11.

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation.

Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E.

Arch Neurol. 2011 Dec;68(12):1550-6. doi: 10.1001/archneurol.2011.182.

PMID:
21825213
12.

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL.

N Engl J Med. 1998 Oct 15;339(16):1105-11.

13.

Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N.

Brain. 2005 Oct;128(Pt 10):2240-9.

14.

Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease.

Molinuevo JL, Valldeoriola F, Tolosa E, Rumia J, Valls-Sole J, Roldan H, Ferrer E.

Arch Neurol. 2000 Jul;57(7):983-8.

PMID:
10891980
15.

Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report.

Alterman RL, Shils JL, Gudesblatt M, Tagliati M.

Neurosurg Focus. 2004 Jul 15;17(1):E6.

PMID:
15264775
16.

Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants.

Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR, Albanese A.

Brain. 2010 Sep;133(9):2664-76. doi: 10.1093/brain/awq221.

17.

Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.

Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G.

Mov Disord. 2006 Jun;21 Suppl 14:S290-304. Review.

PMID:
16892449
18.

Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation.

Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A.

Mov Disord. 2009 Mar 15;24(4):557-63. doi: 10.1002/mds.22390.

PMID:
19097175
19.

Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.

Wider C, Russmann H, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR, Vingerhoets FJ.

Arch Neurol. 2006 Jul;63(7):951-5.

PMID:
16831963
20.

From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.

Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL.

Brain. 1999 Jun;122 ( Pt 6):1133-46.

Items per page

Supplemental Content

Support Center